Key facts
- It has raised $1.4M; the latest was Early Stage VC ($1.4M) in May 2025.
- Notable investors include Shanghai Kehua Biological Engineering.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ArrayHope
- ·The full record, as it builds
Funding rounds
No funding rounds for ArrayHope are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ArrayHope
Operator of a proteomics research platform intended to develop a new generation of autoantibody diagnostic reagents. The company focuses on proteomics research and the construction of high-throughput expression libraries of human full-length proteins, permitting to achieve efficient discovery of early tumor screening markers and development of detection reagents.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2021
- Ownership
- Privately Held (backing)
ArrayHope doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ArrayHope shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ArrayHope in its N-PORT filings yet. We sweep new filings monthly.